皮质神经生理学在不同神经退行性疾病中的分歧与健康的衰老相比
Michael Trubshaw1, Oliver Kohl2, Chetan Gohil2
1Nuffield Department of Clinical Neurosciences, University of Oxford, Oxford, OX3 9DU, UK; Oxford Centre for Human Brain Activity, University of Oxford, Oxford, OX3 7JX, UK.
Progress in neurobiology
|December 5, 2025
概括
磁脑电图 (MEG) 揭示了在阿尔茨海默病 (AD),帕金森病 (PD) 和肌缩侧面硬化症 (ALS) 中不同的大脑活动模式. 这些发现可能会导致神经退行性疾病的早期检测,并作为预防试验的生物标志物.
科学领域:
- 神经科学是一个神经科学.
- 生物标志物 生物标志物
- 脑部成像 脑部成像
背景情况:
- 神经退行性疾病在症状出现之前就破坏了大脑网络的通信.
- 磁脑电图 (MEG) 提供高时空分辨率的非侵入性神经元活动评估.
- 了解健康大脑衰老的偏差对于早期疾病检测至关重要.
研究的目的:
- 与健康对照组 (HC) 相比,对阿尔茨海默氏病 (AD),帕金森病 (PD) 和肌缩性侧面硬化症 (ALS) 中的大脑活动模式的偏差进行表征.
- 探索MEG衍生指标作为神经退行早期生物标志物的潜力.
- 建立神经保护试验的结果措施.
主要方法:
- 29名AD,25名PD,33名ALS患者和191名HC患者的无任务MEG记录.
- 分析光谱功率,连接性,1/f指数和振荡速度.
- 患者组与健康衰老轨迹的比较,对年龄和性别进行控制.
主要成果:
- 与HC相比,所有患者组 (AD,PD,ALS) 呈现出降低的β功率和较慢的振荡活性.
- 肌缩性侧面硬化症 (ALS) 独特地显示了功率光谱倾斜率的降低,与PD和AD的增加不同.
- 在AD和ALS患者中观察到加大了玛连接性.
结论:
- 在不同的神经退行性疾病中,MEG可以检测大脑活动的明显变化.
- 作为一个有希望的生物标志物,MEG可以在早期,可能是症状前的阶段检测神经退行.
- 来自MEG的指标可以在神经退行性疾病的临床试验中作为有价值的结果指标.
相关概念视频
Disorders of the Nervous Tissue
2.5K
Nervous tissue is a vital component of the human body's communication system, enabling us to perceive and respond to stimuli. However, like all other tissues, it is vulnerable to disorders and diseases that can significantly impact our neurological functioning.
Homeostatic Imbalances:
Alzheimer's disease manifests as a gradual decline in memory and cognitive abilities, attributed to the buildup of amyloid plaques and neurofibrillary tangles in the brain.
Parkinson's disease arises from the...
Homeostatic Imbalances:
Alzheimer's disease manifests as a gradual decline in memory and cognitive abilities, attributed to the buildup of amyloid plaques and neurofibrillary tangles in the brain.
Parkinson's disease arises from the...
2.5K
Alzheimer's Disease: Overview
1.6K
Alzheimer's Disease (AD) is a continually advancing neurodegenerative disorder, distinguished by escalating memory loss, cognitive dysfunction, and dementia. The disease unfolds in three stages: preclinical, mild cognitive impairment (MCI), and dementia. Its onset is insidious, and the progression gradual, with the cause not well explained by other disorders.
The clinical diagnosis of AD hinges on the presence of memory and other cognitive impairments. Biomarkers, such as changes in Aβ...
The clinical diagnosis of AD hinges on the presence of memory and other cognitive impairments. Biomarkers, such as changes in Aβ...
1.6K
Neural Regulation
43.0K
Digestion begins with a cephalic phase that prepares the digestive system to receive food. When our brain processes visual or olfactory information about food, it triggers impulses in the cranial nerves innervating the salivary glands and stomach to prepare for food.
43.0K
Pharmacodynamics in Geriatric Patients: Effects of Age
180
Age-related pharmacokinetic changes are extensively documented, but understanding age-related pharmacodynamic alterations is relatively limited. This knowledge gap can be partly attributed to the complexity of developing appropriate measures of drug responses compared to bioanalytical methods for determining drug concentrations.Most information regarding age-related differences in human pharmacodynamics originates from cross-sectional studies. However, these studies assume that observed mean...
180
Cognitive Development During Adulthood
749
Cognitive development continues throughout adulthood, undergoing significant shifts across early, middle, and late stages. Individual transition occurs from adolescent idealism to pragmatic and adaptable thinking in early adulthood. During this period, individuals learn to integrate personal beliefs with the recognition that other perspectives are equally valid. Exposure to the complexities of modern society, diverse experiences, and higher education contribute to this adaptive thought process,...
749


